{"count": 65, "results": [{"_id": "35008822", "pmid": 35008822, "pmcid": "PMC8745385", "title": "Metformin Repurposing for Parkinson Disease Therapy: Opportunities and Challenges", "journal": "Int J Mol Sci", "authors": ["Agostini F", "Masato A", "Bubacco L", "Bisaglia M"], "date": "2021-12-30T00:00:00Z", "doi": "10.3390/ijms23010398", "meta_date_publication": "2021 Dec 30", "meta_volume": "23", "meta_issue": "1", "meta_pages": "", "score": 50278.098, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ Repurposing for @<m>DISEASE_Parkinson_Disease</m> @DISEASE_MESH:D010300 @@@Parkinson Disease@@@ Therapy: Opportunities and Challenges", "citations": {"NLM": "Agostini F, Masato A, Bubacco L, Bisaglia M. Metformin Repurposing for Parkinson Disease Therapy: Opportunities and Challenges Int J Mol Sci. 2021 Dec 30;23(1):. PMID: 35008822", "BibTeX": "@article{35008822, title={Metformin Repurposing for Parkinson Disease Therapy: Opportunities and Challenges}, author={Agostini F and Masato A and Bubacco L and Bisaglia M}, journal={Int J Mol Sci}, volume={23}, number={1}}"}}, {"_id": "32595595", "pmid": 32595595, "pmcid": "PMC7304367", "title": "Metformin as a Potential Neuroprotective Agent in Prodromal Parkinson's Disease:Viewpoint", "journal": "Front Neurol", "authors": ["Sportelli C", "Urso D", "Jenner P", "Chaudhuri KR"], "date": "2020-06-12T00:00:00Z", "doi": "10.3389/fneur.2020.00556", "meta_date_publication": "2020", "meta_volume": "11", "meta_issue": "", "meta_pages": "556", "score": 50275.84, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ as a Potential Neuroprotective Agent in Prodromal @<m>DISEASE_Parkinson_Disease</m> @DISEASE_MESH:D010300 @@@Parkinson's Disease@@@:Viewpoint", "citations": {"NLM": "Sportelli C, Urso D, Jenner P, Chaudhuri KR. Metformin as a Potential Neuroprotective Agent in Prodromal Parkinson's Disease:Viewpoint Front Neurol. 2020;11():556. PMID: 32595595", "BibTeX": "@article{32595595, title={Metformin as a Potential Neuroprotective Agent in Prodromal Parkinson's Disease:Viewpoint}, author={Sportelli C and Urso D and Jenner P and Chaudhuri KR}, journal={Front Neurol}, volume={11}, pages={556}}"}}, {"_id": "35631532", "pmid": 35631532, "pmcid": "PMC9147745", "title": "Dose-Response Association of Metformin with Parkinson's Disease Odds in Type 2 Diabetes Mellitus", "journal": "Pharmaceutics", "authors": ["Huang KH", "Chang YL", "Gau SY", "Tsai TH", "Lee CY"], "date": "2022-04-27T00:00:00Z", "doi": "10.3390/pharmaceutics14050946", "meta_date_publication": "2022 Apr 27", "meta_volume": "14", "meta_issue": "5", "meta_pages": "", "score": 50274.17, "text_hl": "However, studies have also suggested that @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ may increase the risk of @<m>DISEASE_Parkinson_Disease</m> @DISEASE_MESH:D010300 @@@PD@@@. ", "citations": {"NLM": "Huang KH, Chang YL, Gau SY, Tsai TH, Lee CY. Dose-Response Association of Metformin with Parkinson's Disease Odds in Type 2 Diabetes Mellitus Pharmaceutics. 2022 Apr 27;14(5):. PMID: 35631532", "BibTeX": "@article{35631532, title={Dose-Response Association of Metformin with Parkinson's Disease Odds in Type 2 Diabetes Mellitus}, author={Huang KH and Chang YL and Gau SY and Tsai TH and Lee CY}, journal={Pharmaceutics}, volume={14}, number={5}}"}}, {"_id": "32719079", "pmid": 32719079, "pmcid": "PMC7390234", "title": "Association between metformin and neurodegenerative diseases of observational studies: systematic review and meta-analysis", "journal": "BMJ Open Diabetes Res Care", "authors": ["Ping F", "Jiang N", "Li Y"], "date": "2020-07-01T00:00:00Z", "doi": "10.1136/bmjdrc-2020-001370", "meta_date_publication": "2020 Jul", "meta_volume": "8", "meta_issue": "1", "meta_pages": "", "score": 50269.082, "text_hl": "Subgroup analysis showed @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ exposure increased the risk of @<m>DISEASE_Parkinson_Disease</m> @DISEASE_MESH:D010300 @@@Parkinson disease@@@ (@<m>DISEASE_Parkinson_Disease</m> @DISEASE_MESH:D010300 @@@PD@@@) by 66% (OR 1.66, 95% CI 1.14 to 2.42).", "citations": {"NLM": "Ping F, Jiang N, Li Y. Association between metformin and neurodegenerative diseases of observational studies: systematic review and meta-analysis BMJ Open Diabetes Res Care. 2020 Jul;8(1):. PMID: 32719079", "BibTeX": "@article{32719079, title={Association between metformin and neurodegenerative diseases of observational studies: systematic review and meta-analysis}, author={Ping F and Jiang N and Li Y}, journal={BMJ Open Diabetes Res Care}, volume={8}, number={1}}"}}, {"_id": "40465067", "pmid": 40465067, "title": "The Effect of Metformin on Astrocytes in Parkinson's Disease: Challenges and Opportunities.", "journal": "Mol Neurobiol", "authors": ["Al-Kuraishy HM", "Sulaiman GM", "Saad HM", "Mohammed HA", "Abomughaid MM", "Al-Gareeb AI", "Albuhadily AK"], "date": "2025-06-04T00:00:00Z", "doi": "10.1007/s12035-025-05098-8", "meta_date_publication": "2025 Jun 4", "meta_volume": "", "meta_issue": "", "meta_pages": "", "score": 50266.11, "text_hl": "The Effect of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ on Astrocytes in @<m>DISEASE_Parkinson_Disease</m> @DISEASE_MESH:D010300 @@@Parkinson's Disease@@@: Challenges and Opportunities.", "citations": {"NLM": "Al-Kuraishy HM, Sulaiman GM, Saad HM, Mohammed HA, Abomughaid MM, Al-Gareeb AI, Albuhadily AK. The Effect of Metformin on Astrocytes in Parkinson's Disease: Challenges and Opportunities. Mol Neurobiol. 2025 Jun 4;():. PMID: 40465067", "BibTeX": "@article{40465067, title={The Effect of Metformin on Astrocytes in Parkinson's Disease: Challenges and Opportunities.}, author={Al-Kuraishy HM and Sulaiman GM and Saad HM and Mohammed HA and Abomughaid MM and Al-Gareeb AI and Albuhadily AK}, journal={Mol Neurobiol}}"}}, {"_id": "37266747", "pmid": 37266747, "title": "Metformin role in Parkinson's disease: a double-sword effect.", "journal": "Mol Cell Biochem", "authors": ["Alrouji M", "Al-Kuraishy HM", "Al-Gareeb AI", "Ashour NA", "Jabir MS", "Negm WA", "Batiha GE"], "date": "2023-06-02T00:00:00Z", "doi": "10.1007/s11010-023-04771-7", "meta_date_publication": "2023 Jun 2", "meta_volume": "", "meta_issue": "", "meta_pages": "", "score": 50266.11, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ role in @<m>DISEASE_Parkinson_Disease</m> @DISEASE_MESH:D010300 @@@Parkinson's disease@@@: a double-sword effect.", "citations": {"NLM": "Alrouji M, Al-Kuraishy HM, Al-Gareeb AI, Ashour NA, Jabir MS, Negm WA, Batiha GE. Metformin role in Parkinson's disease: a double-sword effect. Mol Cell Biochem. 2023 Jun 2;():. PMID: 37266747", "BibTeX": "@article{37266747, title={Metformin role in Parkinson's disease: a double-sword effect.}, author={Alrouji M and Al-Kuraishy HM and Al-Gareeb AI and Ashour NA and Jabir MS and Negm WA and Batiha GE}, journal={Mol Cell Biochem}}"}}, {"_id": "40760214", "pmid": 40760214, "title": "Metformin as a potential neuroprotective agent that influence Parkinson's disease.", "journal": "Neurol Sci", "authors": ["Pal B", "Ghatak N", "Hossain CM"], "date": "2025-08-04T00:00:00Z", "doi": "10.1007/s10072-025-08370-w", "meta_date_publication": "2025 Aug 4", "meta_volume": "", "meta_issue": "", "meta_pages": "", "score": 50265.92, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ as a potential neuroprotective agent that influence @<m>DISEASE_Parkinson_Disease</m> @DISEASE_MESH:D010300 @@@Parkinson's disease@@@.", "citations": {"NLM": "Pal B, Ghatak N, Hossain CM. Metformin as a potential neuroprotective agent that influence Parkinson's disease. Neurol Sci. 2025 Aug 4;():. PMID: 40760214", "BibTeX": "@article{40760214, title={Metformin as a potential neuroprotective agent that influence Parkinson's disease.}, author={Pal B and Ghatak N and Hossain CM}, journal={Neurol Sci}}"}}, {"_id": "33024014", "pmid": 33024014, "pmcid": "PMC7585014", "title": "Metformin rescues Parkinson's disease phenotypes caused by hyperactive mitochondria", "journal": "Proc Natl Acad Sci U S A", "authors": ["Mor DE", "Sohrabi S", "Kaletsky R", "Keyes W", "Tartici A", "Kalia V", "Miller GW", "Murphy CT"], "date": "2020-10-20T00:00:00Z", "doi": "10.1073/pnas.2009838117", "meta_date_publication": "2020 Oct 20", "meta_volume": "117", "meta_issue": "42", "meta_pages": "26438-26447", "score": 50263.92, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ rescues @<m>DISEASE_Parkinson_Disease</m> @DISEASE_MESH:D010300 @@@Parkinson's disease@@@ phenotypes caused by hyperactive mitochondria", "citations": {"NLM": "Mor DE, Sohrabi S, Kaletsky R, Keyes W, Tartici A, Kalia V, Miller GW, Murphy CT. Metformin rescues Parkinson's disease phenotypes caused by hyperactive mitochondria Proc Natl Acad Sci U S A. 2020 Oct 20;117(42):26438-26447. PMID: 33024014", "BibTeX": "@article{33024014, title={Metformin rescues Parkinson's disease phenotypes caused by hyperactive mitochondria}, author={Mor DE and Sohrabi S and Kaletsky R and Keyes W and Tartici A and Kalia V and Miller GW and Murphy CT}, journal={Proc Natl Acad Sci U S A}, volume={117}, number={42}, pages={26438-26447}}"}}, {"_id": "31843673", "pmid": 31843673, "title": "Emerging neuroprotective effect of metformin in Parkinson's disease: A molecular crosstalk.", "journal": "Pharmacol Res", "authors": ["Paudel YN", "Angelopoulou E", "Piperi C", "Shaikh MF", "Othman I"], "date": "2020-02-01T00:00:00Z", "doi": "10.1016/j.phrs.2019.104593", "meta_date_publication": "2020 Feb", "meta_volume": "152", "meta_issue": "", "meta_pages": "104593", "score": 50263.89, "text_hl": "Emerging neuroprotective effect of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ in @<m>DISEASE_Parkinson_Disease</m> @DISEASE_MESH:D010300 @@@Parkinson's disease@@@: A molecular crosstalk.", "citations": {"NLM": "Paudel YN, Angelopoulou E, Piperi C, Shaikh MF, Othman I. Emerging neuroprotective effect of metformin in Parkinson's disease: A molecular crosstalk. Pharmacol Res. 2020 Feb;152():104593. PMID: 31843673", "BibTeX": "@article{31843673, title={Emerging neuroprotective effect of metformin in Parkinson's disease: A molecular crosstalk.}, author={Paudel YN and Angelopoulou E and Piperi C and Shaikh MF and Othman I}, journal={Pharmacol Res}, volume={152}, pages={104593}}"}}, {"_id": "32497590", "pmid": 32497590, "title": "Metformin regulates astrocyte reactivity in Parkinson's disease and normal aging.", "journal": "Neuropharmacology", "authors": ["Ryu YK", "Go J", "Park HY", "Choi YK", "Seo YJ", "Choi JH", "Rhee M", "Lee TG", "Lee CH", "Kim KS"], "date": "2020-09-15T00:00:00Z", "doi": "10.1016/j.neuropharm.2020.108173", "meta_date_publication": "2020 Sep 15", "meta_volume": "175", "meta_issue": "", "meta_pages": "108173", "score": 50263.867, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ regulates astrocyte reactivity in @<m>DISEASE_Parkinson_Disease</m> @DISEASE_MESH:D010300 @@@Parkinson's disease@@@ and normal aging.", "citations": {"NLM": "Ryu YK, Go J, Park HY, Choi YK, Seo YJ, Choi JH, Rhee M, Lee TG, Lee CH, Kim KS. Metformin regulates astrocyte reactivity in Parkinson's disease and normal aging. Neuropharmacology. 2020 Sep 15;175():108173. PMID: 32497590", "BibTeX": "@article{32497590, title={Metformin regulates astrocyte reactivity in Parkinson's disease and normal aging.}, author={Ryu YK and Go J and Park HY and Choi YK and Seo YJ and Choi JH and Rhee M and Lee TG and Lee CH and Kim KS}, journal={Neuropharmacology}, volume={175}, pages={108173}}"}}]}